Testosterone Therapy for Osteoporosis in Men

January 2010 in “ Elsevier eBooks ”

Kishore M. Lakshman, Shalender Bhasin, Andre B. Araujo

testosterone therapy testosterone dihydrotestosterone DHT androgen

Studysummary Testosterone therapy may help men with osteoporosis.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen, and Sexual Function in Healthy Young Men

research The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen, and Sexual Function in Healthy Young Men

72 citations , April 2008 in “The Journal of urology/The journal of urology”

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

research Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone

417 citations , February 2004 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

research The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

37 citations , May 2002 in “PubMed”

In this study, long-term use of finasteride did not negatively impact bone mineral density in men with benign prostatic hyperplasia over a 4-year period.

The Long-Term Effect of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo-Controlled Trial

research The Long-Term Effect of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo-Controlled Trial

11 citations , May 2002 in “The Journal of Urology”

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

research Discovery of Nonsteroidal Androgens

209 citations , March 1998 in “Biochemical and biophysical research communications”

This study identified a novel class of nonsteroidal ligands that can mimic the effects of dihydrotestosterone on androgen receptors, suggesting potential therapeutic applications in male fertility and hormone replacement therapy.

research Prolonged Treatment with Finasteride (a 5α-Reductase Inhibitor) Does Not Affect Bone Density and Metabolism

48 citations , November 1992 in “Clinical Endocrinology”

Long-term finasteride use doesn't change bone density or metabolism.

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations , October 1992 in “The New England Journal of Medicine”

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.